1. Home
  2. SYRE vs DKL Comparison

SYRE vs DKL Comparison

Compare SYRE & DKL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Spyre Therapeutics Inc.

SYRE

Spyre Therapeutics Inc.

N/A

Current Price

$34.16

Market Cap

2.6B

Sector

Health Care

ML Signal

N/A

DKL

Delek Logistics Partners

N/A

Current Price

$53.07

Market Cap

2.4B

Sector

Energy

ML Signal

N/A

Company Overview

Basic Information
Metric
SYRE
DKL
Founded
2013
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Natural Gas Distribution
Sector
Health Care
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.4B
IPO Year
2016
N/A

Fundamental Metrics

Financial Performance
Metric
SYRE
DKL
Price
$34.16
$53.07
Analyst Decision
Strong Buy
Hold
Analyst Count
6
1
Target Price
$56.50
$45.00
AVG Volume (30 Days)
569.5K
64.5K
Earning Date
02-26-2026
02-27-2026
Dividend Yield
N/A
8.77%
EPS Growth
N/A
9.17
EPS
N/A
3.09
Revenue
N/A
$967,420,000.00
Revenue This Year
N/A
$11.84
Revenue Next Year
N/A
$10.46
P/E Ratio
N/A
$16.60
Revenue Growth
N/A
N/A
52 Week Low
$10.91
$34.59
52 Week High
$35.31
$53.52

Technical Indicators

Market Signals
Indicator
SYRE
DKL
Relative Strength Index (RSI) 57.61 62.33
Support Level $30.92 $50.31
Resistance Level $34.07 $53.52
Average True Range (ATR) 1.80 1.39
MACD -0.03 0.19
Stochastic Oscillator 78.41 72.49

Price Performance

Historical Comparison
SYRE
DKL

About SYRE Spyre Therapeutics Inc.

Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

About DKL Delek Logistics Partners

Delek Logistics Partners LP owns and operates logistics and marketing assets for crude oil and intermediate and refined products. The company's segment includes gathering and processing; wholesale marketing and terminalling; storage and transportation and investment in pipeline joint ventures. It generates maximum revenue from the wholesale marketing and terminalling segment, which provides marketing services for the refined products output of the Delek Holdings' refineries, engages in wholesale activity at its terminals and terminals owned by third parties, whereby it purchases light product for sale and exchange to third parties, and provides terminalling services at its refined products terminals to independent third parties and Delek Holdings.

Share on Social Networks: